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ABSTRACT	  
In	   this	   study,	   we	   evaluate	   the	   potential	   involvement	   of	   collagenase-­‐3	   (MMP13),	   a	   matrix	  
metalloproteinase	   (MMP)	   family	   member,	   in	   the	   exudative	   form	   of	   age-­‐related	   macular	  
degeneration	  (AMD)	  characterized	  by	  a	  neovascularisation	  into	  the	  choroid.	  RT-­‐PCR	  analysis	  revealed	  
that	   human	   neovascular	   membranes	   issued	   from	   patients	   with	   DMLA	   expressed	   high	   levels	   of	  
Mmp13.	  The	  contribution	  of	  MMP13	  in	  choroidal	  neovascularization	  (CNV)	  formation	  was	  explored	  
by	  using	  a	  murine	  model	  of	   laser-­‐induced	  CNV	  and	  applying	  it	  to	  wild	  type	  mice	  (WT)	  and	  Mmp13-­‐
deficient	   mice	   (Mmp13-­‐/-­‐	   mice).	   Angiogenic	   and	   inflammatory	   reactions	   were	   explored	   by	  
immunohistochemistry.	  The	   implication	  of	  bone	  marrow	  (BM)-­‐derived	  cells	  was	  determined	  by	  BM	  
engraftment	   into	   irradiated	  mice	  and	  by	   injecting	  mesenchymal	  stem	  cells	   (MSC)	   isolated	  from	  WT	  
BM.	   The	   deficiency	   of	   Mmp13	   impaired	   CNV	   formation	   which	   was	   fully	   restored	   by	   WT	   BM	  
engraftment	  and	  partially	  rescued	  by	  several	  injections	  of	  WT	  MSC.	  The	  present	  study	  sheds	  light	  on	  
a	  novel	   function	  of	  MMP13	  during	  BM-­‐dependent	   choroidal	   vascularization	  and	  provides	  evidence	  
for	  a	  role	  for	  MSC	  in	  the	  pathogenesis	  of	  CNV.	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Non-­‐standard	  abbreviations	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  bone	  marrow	  ;	  CAM:	  choroiallantoic	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  ;	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  mesenchymal	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   pigmented	   epithelium	   ;	  
TIMP:	  tissue	  inhibitor	  of	  metalloprotease.	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INTRODUCTION	  
Age-­‐related	  macular	  degeneration	  (AMD)	  is	  one	  of	  the	  most	  common	  irreversible	  causes	  of	  
blindness	  among	  people	  over	  50	  years	  [1].	  Ninety	  percents	  of	  all	  vision	  loss	  due	  to	  AMD	  occurs	  in	  the	  
exudative	   form	   which	   is	   characterized	   by	   choroidal	   neovascularization	   (CNV).	   The	   newly	   formed	  
blood	   vessels	   arising	   from	   choriocapillaries	   are	   directed	   to	   the	   subretinal	   macular	   region	   with	  
subsequent	   bleeding	   and/or	   fluid	   leakage	   into	   the	   subretinal	   space,	   local	   retinal	   detachment	   and	  
retinal	  photoreceptor	  damage	  [2].	  The	  pathophysiology	  of	  AMD	  is	  complex	  and	  age-­‐related	  changes	  
that	   induce	   pathologic	   neovascularization	   are	   incompletely	   understood.	   In	   combination	   with	   the	  
rapidly	  growing	  knowledge	  on	  basic	  mechanisms	   in	  angiogenesis,	  new	  evidence	   in	  pathogenesis	  of	  
macular	  disease	  have	  led	  to	  novel	  developments	  in	  therapeutic	  strategies.	  Indeed,	  angiogenic	  factors	  
such	   as	   VEGF	   play	   an	   important	   role	   in	   choroidal	   neovascular	   formation	   [3-­‐5]	   and	   anti-­‐VEGF	  
molecules	   represent	   a	   substantial	   tool	   against	   AMD	   [6].	   In	   the	   process	   of	   CNV,	   the	   vascular	  
overgrowth	   is	   coupled	   with	   a	   localized	   proteolysis,	   extracellular	   remodelling	   and	   cell	   migration	  
involving	  different	  proteolytic	  systems	  among	  which	  the	  matrix	  metalloproteinases	  (MMPs)	  are	  key	  
players	  [7-­‐9].	  	  
An	   involvement	   of	  MMPs	   in	   the	   progression	   of	   retinal	   and	   choroidal	   neovascularization	   is	  
supported	   by	   both	   experimental	   and	   clinical	   data.	   A	  mutation	   of	   Timp-­‐3	   gene	   (tissue	   inhibitor	   of	  
metalloproteinase-­‐3)	   is	   the	   cause	   of	   a	   rare	   familial	   form	   of	   macular	   dystrophy	   associated	   with	  
subretinal	   neovascularisation	   [10-­‐12].	  We	  previously	   reported	   the	   contribution	  of	   different	  MMPs,	  
such	  as	  MMP2	  or	  MMP9,	   in	  a	  mouse	  model	  of	  choroidal	  neovascularisation	  [13].	  Here,	  we	  focused	  
our	   interest	  on	  MMP13,	  an	  important	  collagenase	  displaying	  distinct	  properties	  compared	  with	  the	  
other	   collagenases:	   MMP1	   (interstitial	   collagenase),	   MMP8	   (neutrophil	   collagenase)	   and	   MMP14	  
(MT1-­‐MMP)	  [14].	  MMP13	  has	  the	  capacity	  to	  cleave	  native	  fibrillar	  collagen	  types	   I,	   II,	   III,	  and	  V	  as	  
well	  as	  several	  other	  extracellular	  matrix	  (ECM)	  components,	  including	  type	  IV,	  X,	  and	  XIV	  collagens,	  
large	   tenascin	  C,	   fibronectin,	  aggrecan,	  versican	  and	   fibrillin	   [15-­‐19].	  A	   role	   for	  MMP13	   in	  cartilage	  
matrix	  degradation	  has	  been	  proposed	  based	  on	  its	  expression	  during	  endochondral	  ossification	  and	  
its	  particular	  potential	  to	  degrade	  type	  II	  collagen	  [20;21].	  An	  involvement	  of	  MMP13	  in	  angiogenesis	  
has	  been	  documented	   in	   the	   chorioallantoic	  membrane	   (CAM)	  of	   the	   chick	   embryos	   [22],	   in	   bone	  
fracture	  healing	  [23]	  and	  in	  the	  maintenance	  of	  the	  angiogenic	  response	  induced	  in	  developing	  skin	  
carcinomas	   [24].	   Nevertheless,	   a	   possible	   involvement	   of	   MMP13	   in	   the	   neo-­‐vascularization	  
associated	  with	  ocular	  diseases	  has	  not	  been	  examined.	  
In	   the	   current	   study,	  we	   provide	   evidence	   for	  MMP13	   expression	   in	   late	   stages	   of	   human	  
exudative	  AMD	  and	   investigate	   the	  potential	   role	  of	  MMP13	   in	  choroidal	  angiogenesis	   in	  a	  murine	  
model	   of	   laser-­‐induced	   ocular	   neovascularisation.	  We	   demonstrate	   the	   contribution	   of	  MMP13	   in	  




MATERIAL	  AND	  METHODS	  
Mice  
Homozygous Mmp13-deficient mice (Mmp13-/-) and the corresponding wild-type mice 
(WT) were generated in C57BL/6 background as previously described [25]. Mice expressing a 
single copy of a transgene that encodes the enhanced green fluorescent protein (eGFP) under 
the control of ß-actin promoter C57BL/6-Tg(ACTbEGFP)10sb were obtained from the 
Jackson Laboratories (Bar Harbor, ME). Experimental procedures were performed in 
accordance to the guidelines of the University of Liège regarding the care and use of 
laboratory animals and are in line with the “Ethical principles and guidelines for scientific 
experiments on animals” of the Swiss Academy of Medical Sciences.  
BM Transplantation  
BM cells were isolated from the tibia and femur of donor mice (8 to 10 weeks of age) 
by slowly flushing DMEM culture medium (Gibco BRL, Paisley, UK) into the diaphyseal 
channel. Recipient mice (8 to 10 weeks old) sublethally irradiated with a single dose of 9 Gy 
were injected intravenously (i.v.) with BM cells (107 per animal). At 5 weeks after BM 
transplantation, impact laser burns were performed. The success of BM transplantation was 
assessed as previously described [26]. 
CNV Model  
CNV was induced in both eyes of mice by photocoagulation with laser burns as 
previously described [27]. After 14 days (or earlier time points in kinetic analysis), animals 
were sacrificed and both eyes were enucleated (n = 4 to 8 animals per experimental condition 
with 4 lesions per eye). For immunohistochemical analysis, eyes were embedded in Tissue 
Tek for cryostat sectioning. Neovascularization was estimated by computer-assisted 
measurement on at least five sections per lesion of the b/c ratio (b, thickness from the bottom 
of the pigmented choroidal layer to the top of the neovascular membrane; c, thickness of the 
intact pigmented choroid adjacent to the lesion) as previously described [28-30].  
For confocal visualization of the vasculature, mice were injected intravenously with 
200 µl of fluorescein isothiocyanate (FITC)-conjugated dextran (2 x 103 kd average molecular 
weight, Sigma) (50 mg/ml). After 1 hour of fixation in paraformaldehyde 1% (pH 7.4), retinas 
were removed and choroids were flat-mounted using Vectashield mounting medium (Vector 
Laboratories, Burlingame, CA). Spatial distribution of fluorescence was examined using a 
Leica TCS SP2 inverted confocal laser microscope (Leica Microsystems, Wetzlar, Germany) 
equipped with one argon and two helium-neon lasers and an acousto-optical tuneable filter for 
excitation intensity. FITC was visualized by using an excitation wavelength of 488 nm, and 
the emission light was dispersed and recorded from 500 to 535 nm. For each lesion, serial 
optical sections were recorded with a z-step of 1.67 µm. After successive scanning for each 
interval, three-dimensional fluorescent images were constructed by using Leica confocal 
software. The area and the volume of CNV on choroidal flatmount were determined using the 
image analysis toolbox of MATLAB 7.9 software. 
Human neovascular membranes 
Submacular CNV specimens were obtained during surgery for 360° macular 
translocation performed on patients (n =3) with exudative AMD, either not amenable to 
conventional laser/photodynamic therapy (presence of occult new vessels or submacular 
bleeding) or in one patient, due to a severe recurrence a few months after a successful medical 
treatment [31]. The neovascular membranes were snap frozen in liquid nitrogen and stored at -
80°C. Intact posterior segments from healthy donors (Cornea Bank, Liège, Belgium) collected 
maximum 8 hours after death were used as controls (n = 4). GAPDH was used as a control to 
check for RNA degradation. The methods conformed to the Declaration of Helsinki for 
research involving human subjects. 
RNA extraction in experimental CNV 
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To	   evaluate	   the	   kinetics	   of	   MMP	   expression,	   choroidal	   neovascularization	   was	   induced	   in	  
mice	   by	  multiple	   argon	   laser	   burns	   and	   animals	  were	   killed	   at	   days	   3,	   5,	   10,	   14,	   20,	   and	   40.	   The	  
posterior	   segments	   (RPE-­‐choroid	   complex	   without	   neural	   retina)	   were	   cut	   out	   and	   immediately	  
frozen	   in	   liquid	   nitrogen.	   Total	   RNA	  was	   extracted	   (RNeasy	   extraction	   kit,	   Quiagen,	   Paris,	   France)	  
according	  to	  the	  protocol	  of	  the	  manufacturer.	  	  
In	  some	  assays,	  choroidal	  neovascular	  membranes	  and	  adjacent	  neural	  retina	  intact	  regions	  
were	   separately	   extracted	   from	   frozen	   sections	   by	   laser	   capture	   microdissection	   (laser	   pressure	  
catapulting	  [LPC]	  technique)	  as	  previously	  described	  [32].	  	  Total	  RNA	  isolation	  was	  performed	  (TRIzol	  
Reagent,	  Life	  Technologies,	  Carlsbad,	  California,	  USA)	  according	  to	  the	  manufacturer’s	  protocol.	  	  
	  
RT-­‐PCR	  analysis	  	  
	  
RT-­‐PCR	  was	  done	  on	  10	  ng	  of	  total	  RNA	  extracted	  from	  tissue	  using	  a	  GeneAmp	  Thermostable	  
rTth	   Reverse	   Transcriptase	   RNA	   PCR	   kit	   (Applied	   Biosystems,	   Foster	   City,	   CA)	   following	  
manufacturer's	   instructions.	   Specific	   pairs	   of	   primers	   (Eurogentec,	   Seraing,	   Belgium)	   for	   mouse	  
Mmp13	  were	  designed	  as	  follows:	  forward	  (Exon	  6),	  ATGATCTTTAAAGACAGATTCTTCTGC-­‐3';	  reverse	  
(Exon	  7),	  5'-­‐TGGGATAACCTTCCAGAATGTCATAA-­‐3'.	  Amplification	  of	  35	  cycles	  was	  run	  for	  15	  seconds	  
at	   94°C,	   20	   seconds	   at	   68°C,	   and	   30	   seconds	   at	   72°C.	   Quantification	   of	   Mmp13	   expression	  
quantification	  was	  normalized	   to	  28S	  signal.	  Note	   that	   the	  mutation	   in	  Mmp13-­‐/-­‐	  mice	   is	   in	  Exon	  5	  
that	   encodes	   the	   critical	   catalytic	   domain	  of	   the	   enzyme.	   This	   exon	   is	   spliced	  out	   in	   the	  Mmp13-­‐/-­‐	  
mice	  [33].	  
Immunohistochemistry 
Cryostat sections (6 µm in thickness) were fixed in acetone at –20°C and in methanol 80% at 
4°C before incubation with primary antibodies (Abs). For double-immunofluorescent-
labelling, sections were incubated with two primary Abs. Abs raised against MMP13 (sheep y 
anti mouse, diluted 1/200; home-made Ab from Dr. M.Muller, Heidelberg, Germany), 
PECAM/CD31 (rat anti-mouse, diluted 1/100; BMA, Switzerland), NG2 chondroitin sulfate 
proteoglycan (pericytes, rabbit anti-rat, diluted 1/200; Chemicon, Temecula, CA), -smooth 
muscle actin (FITC-coupled mouse monoclonal, diluted 1/200; Sigma-Aldrich), neutrophils 
(rat anti-mouse, diluted 1/20; Serotec, Oxford, UK), CD11b (biotin-coupled rat anti-mouse, 
diluted 1/250; Pharmingen, San Diego, CA) were incubated for 1 hour at room temperature. 
After washings, the appropriate secondary Abs conjugated to FITC, TRITC or Texas Red 
were applied for 30 minutes, rabbit anti-sheep (dilution 1/500; Cappel Pharmaceuticals), 
swine anti-rabbit (diluted 1/40; Dakopat, Glostrup, Denmark), mouse anti-guinea pig (diluted 
1/40; Sigma), and goat anti-rat (diluted 1/100; Molecular Probes, Eugene, OR). For the 
CD11b labelling, CY3 conjugated streptavidin (diluted 1/200, Sigma) was applied after 
washing the sections. For measurement of vessel coverage with pericytes, automatic 
computer-assisted image analysis was performed in image of lesions obtained after double 
immunostaining for CD31 and NG2. The ratio between the surface of CD31 staining and NG2 
staining was measured by using Aphelio 3.2 software (Asis, France) [34]. 
Isolation and expansion of murine Mesenchymal Stem Cell (MSC)  
MSC were obtained from at least 2 C57Bl/6J mice 8 to 10 weeks old. BM cells were 
isolated from the tibia and femur of donor mice as described above for BM transplantation. 
BM cells were filtrated and plated in Mesencult medium (StemCell Technologies Inc, 
Vancouver, Canada). After 24h, nonadherent cells were removed by washing with phosphate-
buffered saline (PBS) and fresh medium was added. MSC were used from passages 6 to 10. 
MSC phenotype was characterised by immunostaining and FACS analysis (CD106+, Sca1+, 
CD34-, CD45-, CD11b-). Osteogenic, adipogenic and chondrogenic differentiation assays 
were performed on MSC as previously described [35]. 
Statistical analyses  
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Data were analyzed with GraphPad Prism 4.0 (San Diego, CA). The unpaired 
Student’s t test was used to determine the significance (p<0.05) of differences between 
experimental groups (* : p<0.05; ** : p<0.01; *** : p<0.001). 
 
RESULTS 
Mmp13 is expressed in human neovascular membranes and in mouse choroidal 
neovascular lesions induced by laser burn 
Mmp13 mRNAs expression was evaluated on submacular CNV specimens collected 
on AMD patients during surgery for 360° macular translocation. Mmp13 mRNAs were 
strongly expressed in all human CNV specimens analysed (Figure 1A). In sharp contrast, a 
faint basal expression of Mmp13 mRNA was detected in some control specimens (in or out of 
the macula) collected from healthy donors. The expression of 28S rRNA and Gapdh mRNA 
was used as a control to assess the good preservation of mRNA in AMD patients and healthy 
donors. 
In mouse, photocoagulation with an argon laser induced a trauma leading to the 
formation of choroidal neovascular lesions (CNV) under the retina. RT-PCR analysis revealed 
that levels of Mmp13 mRNA were low in the early stage of CNV formation and then 
progressively increased from day 5 to day 7 (p< 0.05). From day 7 to day 14, coinciding with 
the period of CNV stabilization, Mmp13 mRNA levels did not progress anymore (p= 0.3627) 
(n=8) (Fig.1A). Mmp13 mRNAs were specifically detected on microdissected neovascular 
choroidal membranes from WT mice, but not from Mmp13-/- mice. Neighbouring intact 
chorioretinal areas were negative for Mmp13 mRNA, confirming that Mmp13 expression was 
locally induced during the photocoagulation (Fig.1B). Immunohistochemical analysis 
confirmed the presence of MMP13 protein in the neovascular lesions in WT mice (Fig.3A, B). 
Mmp13-deficiency impairs choroidal neovascularization 
Retinal damage and choroidal neovascularization were estimated by measuring 
different parameters: the area of CNV on choroidal flatmounts observed by confocal 
microscopy (Fig.2A) and the ratio between the maximal height of the lesion (b) and the 
thickness od the normal choroid (c) observed in the neighbouring intact zones (b/c ratio) 
determined on tissue sections (Fig.2B) [36]. A reduced neovascularization was observed in 
Mmp13-/- mice as compared to WT mice. The analysis by confocal microscopy of flatmounted 
choroids revealed a two-fold reduction of vessel area (Fig.2A). Similar results were obtained 
by measuring the volume of vascularisation through a 3D analysis (0.11x106 µm³ ± 0.03x106 
SEM in WT mice versus 0.05x106 µm³ ± 0.01x106 SEM in Mmp13-/- mice; p=0.047). The 
severity of neovascularisation was also estimated histologically on serial sections by 
measuring the maximal height of lesion (b) above the thickness of the normal choroid 
observed in neighbouring intact zones (c). In Mmp13–/– mice, the b/c ratio was significantly 
reduced in comparison to WT mice (P < 0.0001) (Fig.2B). Newly formed blood vessels were 
characterized by immunostaining of endothelial cells (PECAM positive cells) and 
perivascular cells (αSMA positive cells) or pericytes (NG2 positive cells) (fig.3C-F). While 
newly formed vessels were "naked" in Mmp13-/- mice, they were covered by NG2+ cells and 
αSMA+ cells in WT mice. Indeed, the percentage of NG2/SMA co-localization was 10-fold 
higher in WT mice as compared to Mmp13-/- mice (9.18±3.45 in WT versus 0.97±0.39 in KO 
mice). These results reveal that Mmp13 deficiency not only affected vessel recruitment, but 
also impaired their maturation through pericyte coverage. 
The inflammatory reaction was next explored by immunostaining of CD11b 
(Fig.3G,H) and neutrophils (Fig.3I,J). In accordance with our previous data [37], 
inflammatory cells were not detected before injury induction (at day 0) and appeared at day 3 
post-injury. No significant difference in the number of inflammatory CD11b+ cells was 
observed in Mmp13-deficient mice (0.077 ± 0.006 CD11b+ cells per mm² and 0.064 ± 0.005 
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cells neutrophils per mm²) compared to the WT mice (0.051 ± 0.003 cells CD11b+ cells per 
mm² and 0.048 ± 0.009 cells neutrophils per mm²) (p>0.05).  
 
WT bone marrow-derived cells rescue choroidal angiogenesis in Mmp13-deficient 
mice 
BM was harvested from WT mice and RT-PCR analysis revealed Mmp13 expression 
in BM cells. WT or Mmp13-/- mice were irradiated and transplanted with unfractionned BM 
issued from WT or Mmp13-/- mice. Five weeks after BM transplantation (i.e., after allowing 
for BM reconstitution), laser burns were performed to induce CNV. Genotyping of spleen was 
performed for all animals to assess BM transplantation success. New blood vessel formation 
was quantified by both flatmount and histological analysis. When irradiated mice were 
reconstituted with BM from WT mice, a slight decrease but not significant (P>0.05) in vessel 
formation was observed in grafted mice as compared to ungrafted mice (Fig.4). Interestingly, 
a complete restoration of the CNV was observed in Mmp13-/- mice engrafted with WT BM. In 
this experimental group, the CNV formation was similar to that observed in WT mice 
engrafted with WT BM and significantly higher than that of Mmp13-/- mice engrafted with 
Mmp13-/- BM (p=0.0097). Moreover, the engraftment of MMP13-deficient BM into WT mice 
significantly decreased CNV formation in comparison to WT control mice (p=0.0009) (Fig.4). 
Similar results were obtained by evaluating CNV formation through confocal analysis of 
flatmount choroids (fig.4A) and through histological analysis of eye sections (fig.4B). 
Bone marrow-derived MSC are implicated in Mmp13-mediated choroidal 
angiogenesis 
Effects	  of	  BM-­‐produced	  MMP13	  could	  be	  either	  attributed	  to	  hematopoietic	  cells	  but	  also	  to	  
mesenchymal	   stem	   cells	   (MSC).	   It	   has	   been	   described	   that	   MMP13	   is	   mainly	   expressed	   by	  
mesenchymal	  cells	   [38].	  To	  provide	  new	   insights	   into	   the	  type	  of	  BM-­‐derived	  cells	   involved	   in	  CNV	  
formation,	  we	   isolated	   (MSC)	   from	  WT	   BM.	   The	   expression	   of	  Mmp13	   by	  MSC	   cultured	   cells	  was	  
assessed	  by	  RT-­‐PCR	  analysis.	  Mmp13	  mRNA	  is	  more	  expressed	  by	  isolated	  MSC	  than	  by	  whole	  bone	  
marrow	   (Fig.5B).	   MSC	   were	   then	   intravenously	   injected	   at	   days	   1,	   3,	   7	   and	   10	   post	   laser	   injury.	  
Interestingly,	  MSC	  injection	  into	  WT	  mice	  did	  not	  affect	  CNV	  formation	  (Fig.5A).	  In	  contrast,	  a	  partial	  
restoration	  of	  CNV	  formation	  was	  observed	  in	  Mmp13-­‐deficient	  mice	  injected	  with	  WT	  MSC.	  These	  





Through	   a	   genetic	   approach,	   the	   present	   study	   provides	   evidences	   for	   a	   contribution	   of	  
MMP13	  during	  BM-­‐dependent	  choroidal	  neovascularization	  in	  a	  mouse	  model	  of	  laser	  burn-­‐induced	  
CNV.	  This	  concept	  is	  supported	  by	  [1]	  the	  increased	  expression	  of	  Mmp13	  during	  the	  course	  of	  CNV	  
induction,	  [2]	  the	  impaired	  CNV	  in	  Mmp13-­‐/-­‐	  mice	  and	  [3]	  the	  restoration	  of	  CNV	  in	  Mmp13-­‐/-­‐	  mice	  by	  
the	  engraftment	  of	  BM	  or	  the	  injection	  of	  MSC	  derived	  from	  WT	  mice.	  These	  experimental	  findings	  
are	  consistent	  with	  the	  expression	  of	  MMP13	  detected	  in	  late	  stages	  of	  human	  exudative	  AMD.	  	  
The	   contribution	   of	   MMP13	   in	   angiogenesis	   has	   been	   previously	   documented	   in	   a	  
physiological	  model	  of	  angiogenesis,	  the	  chorioallantoic	  membrane	  (CAM)	  assay	  [39].	  In	  this	  system,	  
purified	   chicken	  MMP13	   elicited	   an	   angiogenic	   response	   in	   the	   CAM	   onplant	   comparable	   to	   that	  
induced	  by	  angiogenic	  growth	  factors.	  In	  line	  with	  our	  finding	  of	  angiogenesis	  dysfunction	  in	  Mmp13-­‐
deficient	  mice,	  is	  the	  observation	  of	  defective	  vascular	  penetration	  into	  the	  fracture	  callus	  observed	  
in	  a	  murine	  model	  of	  bone	  fracture	  healing	  [40],	  impaired	  tumoral	  angiogenesis	  in	  murine	  models	  of	  
skin	   carcinomas	   [41]	   and	   delayed	   vascularization	   of	   primary	   ossification	   centres	   in	  Mmp13-­‐/-­‐	  mice	  
during	   embryonic	   development	   [42].	   Our	   work	   extends	   the	   role	   of	   MMP13	   to	   pathological	  
angiogenesis	  and	  specifically	  to	  ocular	  diseases	  such	  as	  AMD.	  	  
The	   action	   of	  MMP13	   in	   CNV	   can	   involve	   different	  mechanisms.	   As	   a	   principal	   interstitial	  
collagenase,	   MMP13	   could	   contribute	   to	   tissue	   remodelling	   paving	   the	   way	   for	   endothelial	   cell	  
migration.	  We	  found,	  however,	  that	  collagen	  deposition	  assessed	  by	  safranin	  staining	  did	  not	  reveal	  
differences	   between	   genotypes	   (data	   not	   shown).	   MMP13	   could	   also	   participate	   in	   a	   proteolysis	  
cascade	  including	  MT1-­‐MMP,	  MMP2	  and	  MMP9	  [43].	  Indeed,	  the	  latter	  MMPs	  could	  have	  the	  most	  
critical	   function	   in	   extracellular	   matrix	   remodelling	   occurring	   during	   angiogenesis	   associated	   with	  
AMD.	  In	  this	  context,	  we	  previously	  reported	  the	  key	  contribution	  of	  MMP2	  and	  MMP9	  in	  CNV	  [44].	  
A	  pro-­‐angiogenic	  effect	  of	  MMP13	  may	  also	  require	  release	  from	  cryptic	  sites	  of	  angiogenic	  factors	  
such	  as	  bFGF	  [45]	  or	  VEGF	  [46].	  A	  combination	  of	  different	  mechanisms	  of	  action	  cannot	  be	  excluded.	  
The	  present	  demonstration	  that	  MMP13	  plays	  a	  role	   in	  CNV	  provides	  an	   incentive	  to	  further	  study	  
the	  mechanisms	  underlying	  the	  pro-­‐angiogenic	  functions	  of	  MMP13.	  
An	   unexpected	   finding	   of	   our	   work	   is	   the	   contribution	   of	   BM-­‐derived	   cells	   to	   the	   pro-­‐
angiogenic	   action	   of	  MMP13.	   The	   formation	   of	   choroidal	   neovascularization	  may	   involve	   different	  
mechanisms	   such	   as	   angiogenesis	   (the	   endothelial	   cell	   spouting	   from	   pre-­‐existing	   vessels)	   and	  
vasculogenesis	   (the	   recruitment	   of	   BM-­‐derived	   cells)	   [47-­‐49].	   We	   and	   others	   previously	  
demonstrated	   the	   recruitment	   of	   BM-­‐derived	   cells	   in	   CNV	   [50-­‐54].	   These	   observations	   are	   further	  
supported	  by	  previous	  experiments	  in	  which	  GFP+	  BM	  cells	  were	  engrafted	  into	  WT	  mice	  [54-­‐58].	  Of	  
interest	   is	   the	   demonstration	   here	   that	   WT	   BM-­‐derived	   cells	   are	   sufficient	   to	   restore	   the	  
vascularization	  impaired	  by	  Mmp13	  deficiency.	  This	  report	  provides	  the	  first	  experimental	  evidence	  
for	  a	  key	  role	  played	  by	  BM-­‐derived	  MMP13	  in	  pathological	  ocular	  vascularization.	  This	  is	  in	  line	  with	  
the	  levels	  of	  MMP13	  expression	  reported	  in	  BM-­‐derived	  cells	  that	  contributed	  to	  the	  pathology	  in	  a	  
model	  of	  liver	  fibrosis	  [59].	  It	  is	  worth	  noting	  that	  whole	  body	  irradiation	  followed	  by	  bone	  marrow	  
reconstitution	   can	   potentially	   affect	   neovascularization.	   Indeed,	   radiation	   is	   well	   known	   to	   cause	  
damage	  to	  endothelial	  cells	  and	  to	  inhibit	  neovascularization	  by	  suppressing	  the	  recruitment	  of	  bone	  
marrow-­‐derived	   endothelial	   cells	   [60].	   Accordingly,	   a	   slight	   radiation-­‐induced	   defect	   in	  
neovascularization	   was	   observed	   in	   the	   present	   model.	   The	   present	   study	   demonstrates	   that	  
Mmp13-­‐/-­‐	  mice	  engrafted	  with	  WT	  BM	  displayed	  similar	  CNV	  formation	  than	  WT	  mice	  engrafted	  with	  
WT	  BM	  revealing	  a	  restoration	  of	  the	  angiogenic	  response	  through	  BM	  transplantation.	  
	  The	  effect	  of	  BM-­‐derived	  cells	  could	  be	  attributed	  to	  MSC,	  vascular	  progenitor	  cells	  and/or	  
inflammatory	   cells	   which	   could	   migrate	   into	   reconstituted	   tissues	   or	   secrete	   soluble	   factors	   that	  
mediate	  inflammation	  and	  angiogenesis.	  We	  previously	  demonstrated	  that	  several	  BM-­‐derived	  cells	  
could	   contribute	   to	   CNV	   development,	   such	   as	   inflammatory	   CD11b	   positive	   cells	   and/or	  
mesenchymal	   cells	  positive	   for	  αSMA	   (myofibroblasts	  or	  vascular	   smooth	  muscle	   cells)	   [61].	   In	   the	  
current	   study,	  we	   demonstrate	   the	   key	   role	   in	   CNV	   formation	   played	   by	  Mmp13-­‐expressing	  MSC.	  
Indeed,	   four	   repetitive	   injections	   of	   MSC	   derived	   from	  WT	   mice	   partially	   rescued	   the	   impaired	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angiogenic	   phenotype	   in	  Mmp13-­‐/-­‐	   mice.	   This	   partial	   restoration	   achieved	   with	   MSC	   injection	   as	  
compared	   to	   the	   complete	   restoration	   of	   the	   phenotype	   achieved	  with	   BM	  engraftment	   could	   be	  
explained	   either	   by	   a	   combined	   effect	   of	   different	   types	   of	   BM-­‐derived	   cells,	   a	   transient	   effect	   of	  
MSC	   or	   an	   insufficient	   supplementation	   of	   MSC	   through	   cell	   injections.	   Nevertheless,	   these	   data	  
point	  to	  a	  novel	  role	  for	  MSC	  in	  CNV.	  	  
In	  conclusion,	  we	  have	   identified	  MMP13	  as	  a	  key	  regulator	  of	  choroidal	  angiogenesis.	  Our	  
findings	  extend	  the	  potential	  roles	  of	  MMP13	  initially	  observed	  in	  cartilage/bone	  resorption	  [62]	  and	  
tumor	  development	  [63;64]	  to	  ocular	  diseases	  such	  as	  AMD.	  This	  pro-­‐angiogenic	  effect	  of	  MMP13	  is	  
mainly	   mediated	   by	   BM-­‐derived	  mesenchymal	   cells.	   These	   findings	   pave	   the	   way	   for	   therapeutic	  
strategies	   based	   on	   the	   targeting	   of	   MMP13	   with	   synthetic	   inhibitors	   or	   on	   the	   use	   of	   MSC	   as	  




The	  authors	  acknowledge	  P.	  Gavitelli,	  F.	  Olivier,	  M.-­‐R.	  Pignon,	  E.	  Feiyereisen,	  L.	  Poma,	  G.	  Roland	  and	  
N.	  Lefin	  for	  collaboration	  and	  technical	  assistance.	  They	  thank	  the	  GIGA	  imaging	  and	  flow	  cytometry	  
platform	   for	   their	   help.	   This	  work	  was	   supported	   by	   grants	   from	   the	   European	  Union	   Framework	  
Program	   	   projects	   (FP7,	   MICROENVIMET),	   the	   Fonds	   de	   la	   Recherche	   Scientifique	   Médicale,	   the	  
Fonds	   National	   de	   la	   Recherche	   Scientifique	   (F.N.R.S.,	   Belgium),	   the	   Federation	   belge	   contre	   le	  
Cancer,	   the	   Fonds	   spéciaux	   de	   la	   Recherche	   (University	   of	   Liège),	   the	   Centre	   Anticancéreux	   près	  
l'Université	  de	  Liège,	  the	  Fonds	  Léon	  Fredericq	  (University	  of	  Liège),	  the	  D.G.T.R.E.	  from	  the	  «	  Région	  
Wallonne	  »,	  the	  Interuniversity	  Attraction	  Poles	  Program	  -­‐	  Belgian	  Science	  Policy	  (Brussels,	  Belgium).	  








	   1.	  	   Bressler	  NM	  (2004)	  Age-­‐related	  macular	  degeneration	  is	  the	  leading	  cause	  of	  blindness..	  JAMA,	  
291:	  1900-­‐1901.	  
	   2.	  	   Rattner	   A,	   Nathans	   J	   (2006)	   Macular	   degeneration:	   recent	   advances	   and	   therapeutic	  
opportunities.	  Nat.	  Rev.	  Neurosci.,	  7:	  860-­‐872.	  
	   3.	  	   Ferrara	  N,	  Kerbel	  RS	  (2005)	  Angiogenesis	  as	  a	  therapeutic	  target.	  Nature,	  438:	  967-­‐974.	  
	   4.	  	   Noel	  A,	   Jost	  M,	   Lambert	  V,	   Lecomte	   J,	  Rakic	   JM	   (2007)	  Anti-­‐angiogenic	   therapy	  of	   exudative	  
age-­‐related	  macular	  degeneration:	  current	  progress	  and	  emerging	  concepts.	  Trends	  Mol.	  Med.,	  
13:	  345-­‐352.	  
	   5.	  	   Rakic	   JM,	   Lambert	   V,	   Devy	   L,	   Luttun	   A,	   Carmeliet	   P,	   Claes	   C,	   Nguyen	   L,	   Foidart	   JM,	   Noel	   A,	  
Munaut	   C	   (2003)	   Placental	   growth	   factor,	   a	  member	   of	   the	   VEGF	   family,	   contributes	   to	   the	  
development	  of	  choroidal	  neovascularization.	  Invest	  Ophthalmol.	  Vis.	  Sci.,	  44:	  3186-­‐3193.	  
	   6.	  	   Noel	  A,	   Jost	  M,	   Lambert	  V,	   Lecomte	   J,	  Rakic	   JM	   (2007)	  Anti-­‐angiogenic	   therapy	  of	   exudative	  
age-­‐related	  macular	  degeneration:	  current	  progress	  and	  emerging	  concepts.	  Trends	  Mol.	  Med.,	  
13:	  345-­‐352.	  
	   7.	  	   Rundhaug	  JE	  (2005)	  Matrix	  metalloproteinases	  and	  angiogenesis.	  J.	  Cell	  Mol.	  Med.,	  9:	  267-­‐285.	  
	   8.	  	   Raffetto	   JD,	   Khalil	   RA	   (2008)	   Matrix	   metalloproteinases	   and	   their	   inhibitors	   in	   vascular	  
remodeling	  and	  vascular	  disease.	  Biochem.	  Pharmacol.,	  75:	  346-­‐359.	  
	   9.	  	   Noel	  A,	   Jost	  M,	   Lambert	  V,	   Lecomte	   J,	  Rakic	   JM	   (2007)	  Anti-­‐angiogenic	   therapy	  of	   exudative	  
age-­‐related	  macular	  degeneration:	  current	  progress	  and	  emerging	  concepts.	  Trends	  Mol.	  Med.,	  
13:	  345-­‐352.	  
 10 
	   10.	  	   Das	  A,	  McGuire	  PG,	  Eriqat	  C,	  Ober	  RR,	  DeJuan	  E	  Jr,	  Williams	  GA,	  McLamore	  A,	  Biswas	  J,	  Johnson	  
DW	   (1999)	   Human	   diabetic	   neovascular	   membranes	   contain	   high	   levels	   of	   urokinase	   and	  
metalloproteinase	  enzymes.	  Invest	  Ophthalmol.	  Vis.	  Sci.,	  40:	  809-­‐813.	  
	   11.	  	   Kadonosono	   K,	   Yazama	   F,	   Itoh	   N,	   Sawada	   H,	   Ohno	   S	   (1999)	   Expression	   of	   matrix	  
metalloproteinase-­‐7	   in	   choroidal	   neovascular	   membranes	   in	   age-­‐related	   macular	  
degeneration.	  Am.	  J.	  Ophthalmol.,	  128:	  382-­‐384.	  
	   12.	  	   Weber	   BH,	   Vogt	   G,	   Pruett	   RC,	   Stohr	   H,	   Felbor	   U	   (1994)	  Mutations	   in	   the	   tissue	   inhibitor	   of	  
metalloproteinases-­‐3	  (TIMP3)	  in	  patients	  with	  Sorsby's	  fundus	  dystrophy.	  Nat.	  Genet.,	  8:	  352-­‐
356.	  
	   13.	  	   Lambert	  V,	  Wielockx	  B,	  Munaut	  C,	  Galopin	  C,	   Jost	  M,	   Itoh	  T,	  Werb	  Z,	  Baker	  A,	   Libert	  C,	  Krell	  
HW,	  Foidart	  JM,	  Noel	  A,	  Rakic	  JM	  (2003)	  MMP-­‐2	  and	  MMP-­‐9	  synergize	  in	  promoting	  choroidal	  
neovascularization.	  FASEB	  J.,	  17:	  2290-­‐2292.	  
	   14.	  	   Overall	  CM,	  Lopez-­‐Otin	  C	   (2002)	  Strategies	   for	  MMP	   inhibition	   in	  cancer:	   innovations	   for	   the	  
post-­‐trial	  era.	  Nat.	  Rev.	  Cancer,	  2:	  657-­‐672.	  
	   15.	  	   Fosang	  AJ,	  Last	  K,	  Knauper	  V,	  Murphy	  G,	  Neame	  PJ	  (1996)	  Degradation	  of	  cartilage	  aggrecan	  by	  
collagenase-­‐3	  (MMP-­‐13).	  FEBS	  Lett.,	  380:	  17-­‐20.	  
	   16.	  	   Knauper	  V,	  Smith	  B,	  Lopez-­‐Otin	  C,	  Murphy	  G	  (1997)	  Activation	  of	  progelatinase	  B	  (proMMP-­‐9)	  
by	  active	  collagenase-­‐3	  (MMP-­‐13).	  Eur.	  J.	  Biochem.,	  248:	  369-­‐373.	  
	   17.	  	   Ashworth	  JL,	  Murphy	  G,	  Rock	  MJ,	  Sherratt	  MJ,	  Shapiro	  SD,	  Shuttleworth	  CA,	  Kielty	  CM	  (1999)	  
Fibrillin	   degradation	   by	   matrix	   metalloproteinases:	   implications	   for	   connective	   tissue	  
remodelling.	  Biochem.	  J.,	  340	  (	  Pt	  1):	  171-­‐181.	  
	   18.	  	   Leeman	   MF,	   Curran	   S,	   Murray	   GI	   (2002)	   The	   structure,	   regulation,	   and	   function	   of	   human	  
matrix	  metalloproteinase-­‐13.	  Crit	  Rev.	  Biochem.	  Mol.	  Biol.,	  37:	  149-­‐166.	  
	   19.	  	   Cowell	  S,	  Knauper	  V,	  Stewart	  ML,	  D'Ortho	  MP,	  Stanton	  H,	  Hembry	  RM,	  Lopez-­‐Otin	  C,	  Reynolds	  
JJ,	   Murphy	   G	   (1998)	   Induction	   of	   matrix	   metalloproteinase	   activation	   cascades	   based	   on	  
membrane-­‐type	  1	  matrix	  metalloproteinase:	  associated	  activation	  of	  gelatinase	  A,	  gelatinase	  B	  
and	  collagenase	  3.	  Biochem.	  J.,	  331	  (	  Pt	  2):	  453-­‐458.	  
	   20.	  	   Takaishi	   H,	   Kimura	   T,	   Dalal	   S,	   Okada	   Y,	   D'Armiento	   J	   (2008)	   Joint	   diseases	   and	   matrix	  
metalloproteinases:	  a	  role	  for	  MMP-­‐13.	  Curr.	  Pharm.	  Biotechnol.,	  9:	  47-­‐54.	  
	   21.	  	   Kosaki	  N,	  Takaishi	  H,	  Kamekura	  S,	  Kimura	  T,	  Okada	  Y,	  Minqi	  L,	  Amizuka	  N,	  Chung	  UI,	  Nakamura	  
K,	   Kawaguchi	   H,	   Toyama	   Y,	   D'Armiento	   J	   (2007)	   Impaired	   bone	   fracture	   healing	   in	   matrix	  
metalloproteinase-­‐13	  deficient	  mice.	  Biochem.	  Biophys.	  Res.	  Commun.,	  354:	  846-­‐851.	  
	   22.	  	   Zijlstra	  A,	  Aimes	  RT,	  Zhu	  D,	  Regazzoni	  K,	  Kupriyanova	  T,	   Seandel	  M,	  Deryugina	  EI,	  Quigley	   JP	  
(2004)	   Collagenolysis-­‐dependent	   angiogenesis	   mediated	   by	   matrix	   metalloproteinase-­‐13	  
(collagenase-­‐3).	  J.	  Biol.	  Chem.,	  279:	  27633-­‐27645.	  
	   23.	  	   Kosaki	  N,	  Takaishi	  H,	  Kamekura	  S,	  Kimura	  T,	  Okada	  Y,	  Minqi	  L,	  Amizuka	  N,	  Chung	  UI,	  Nakamura	  
K,	   Kawaguchi	   H,	   Toyama	   Y,	   D'Armiento	   J	   (2007)	   Impaired	   bone	   fracture	   healing	   in	   matrix	  
metalloproteinase-­‐13	  deficient	  mice.	  Biochem.	  Biophys.	  Res.	  Commun.,	  354:	  846-­‐851.	  
	   24.	  	   Lederle	   W,	   Hartenstein	   B,	   Meides	   A,	   Kunzelmann	   H,	   Werb	   Z,	   Angel	   P,	   Mueller	   MM	   (2009)	  
MMP13	   as	   a	   stromal	   mediator	   in	   controlling	   persistent	   angiogenesis	   in	   skin	   carcinoma.	  
Carcinogenesis.	  
	   25.	  	   Inada	  M,	  Wang	  Y,	  Byrne	  MH,	  Rahman	  MU,	  Miyaura	  C,	  Lopez-­‐Otin	  C,	  Krane	  SM	  (2004)	  Critical	  
roles	  for	  collagenase-­‐3	  (Mmp13)	  in	  development	  of	  growth	  plate	  cartilage	  and	  in	  endochondral	  
ossification.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A,	  101:	  17192-­‐17197.	  
	   26.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   27.	  	   Lambert	   V,	   Munaut	   C,	   Noel	   A,	   Frankenne	   F,	   Bajou	   K,	   Gerard	   R,	   Carmeliet	   P,	   Defresne	  MP,	  
Foidart	   JM,	  Rakic	   JM	   (2001)	   Influence	  of	  plasminogen	  activator	   inhibitor	   type	  1	  on	  choroidal	  
neovascularization.	  FASEB	  J.,	  15:	  1021-­‐1027.	  
 11 
	   28.	  	   Lambert	  V,	  Wielockx	  B,	  Munaut	  C,	  Galopin	  C,	   Jost	  M,	   Itoh	  T,	  Werb	  Z,	  Baker	  A,	   Libert	  C,	  Krell	  
HW,	  Foidart	  JM,	  Noel	  A,	  Rakic	  JM	  (2003)	  MMP-­‐2	  and	  MMP-­‐9	  synergize	  in	  promoting	  choroidal	  
neovascularization.	  FASEB	  J.,	  17:	  2290-­‐2292.	  
	   29.	  	   Rakic	  JM,	  Maillard	  C,	  Jost	  M,	  Bajou	  K,	  Masson	  V,	  Devy	  L,	  Lambert	  V,	  Foidart	  JM,	  Noel	  A	  (2003)	  
Role	   of	   plasminogen	   activator-­‐plasmin	   system	   in	   tumor	   angiogenesis.	   Cell	  Mol.	   Life	   Sci.,	   60:	  
463-­‐473.	  
	   30.	  	   Rakic	   JM,	   Lambert	   V,	   Devy	   L,	   Luttun	   A,	   Carmeliet	   P,	   Claes	   C,	   Nguyen	   L,	   Foidart	   JM,	   Noel	   A,	  
Munaut	   C	   (2003)	   Placental	   growth	   factor,	   a	  member	   of	   the	   VEGF	   family,	   contributes	   to	   the	  
development	  of	  choroidal	  neovascularization.	  Invest	  Ophthalmol.	  Vis.	  Sci.,	  44:	  3186-­‐3193.	  
	   31.	  	   Rakic	   JM,	   Lambert	   V,	   Munaut	   C,	   Bajou	   K,	   Peyrollier	   K,	   Alvarez-­‐Gonzalez	   ML,	   Carmeliet	   P,	  
Foidart	   JM,	   Noel	   A	   (2003)	   Mice	   without	   uPA,	   tPA,	   or	   plasminogen	   genes	   are	   resistant	   to	  
experimental	  choroidal	  neovascularization.	  Invest	  Ophthalmol.	  Vis.	  Sci.,	  44:	  1732-­‐1739.	  
	   32.	  	   Lambert	   V,	   Munaut	   C,	   Jost	   M,	   Noel	   A,	   Werb	   Z,	   Foidart	   JM,	   Rakic	   JM	   (2002)	   Matrix	  
metalloproteinase-­‐9	   contributes	   to	   choroidal	   neovascularization.	   Am.	   J.	   Pathol.,	   161:	   1247-­‐
1253.	  
	   33.	  	   Inada	  M,	  Wang	  Y,	  Byrne	  MH,	  Rahman	  MU,	  Miyaura	  C,	  Lopez-­‐Otin	  C,	  Krane	  SM	  (2004)	  Critical	  
roles	  for	  collagenase-­‐3	  (Mmp13)	  in	  development	  of	  growth	  plate	  cartilage	  and	  in	  endochondral	  
ossification.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A,	  101:	  17192-­‐17197.	  
	   34.	  	   El	  Hour	  M,	  Moncada-­‐Pazos	  A,	  Blacher	  S,	  Masset	  A,	  Cal	  S,	  Berndt	  S,	  Detilleux	  J,	  Host	  L,	  Obaya	  AJ,	  
Maillard	  C,	   Foidart	   JM,	  Ectors	  F,	  Noel	  A,	   Lopez-­‐Otin	  C	   (2010)	  Higher	   sensitivity	  of	  Adamts12-­‐
deficient	  mice	  to	  tumor	  growth	  and	  angiogenesis.	  Oncogene.	  
	   35.	  	   Peister	  A,	  Mellad	   JA,	  Larson	  BL,	  Hall	  BM,	  Gibson	  LF,	  Prockop	  DJ	   (2004)	  Adult	   stem	  cells	   from	  
bone	  marrow	   (MSCs)	   isolated	   from	  different	   strains	  of	   inbred	  mice	   vary	   in	   surface	  epitopes,	  
rates	  of	  proliferation,	  and	  differentiation	  potential.	  Blood,	  103:	  1662-­‐1668.	  
	   36.	  	   Rakic	   JM,	   Lambert	   V,	   Devy	   L,	   Luttun	   A,	   Carmeliet	   P,	   Claes	   C,	   Nguyen	   L,	   Foidart	   JM,	   Noel	   A,	  
Munaut	   C	   (2003)	   Placental	   growth	   factor,	   a	  member	   of	   the	   VEGF	   family,	   contributes	   to	   the	  
development	  of	  choroidal	  neovascularization.	  Invest	  Ophthalmol.	  Vis.	  Sci.,	  44:	  3186-­‐3193.	  
	   37.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   38.	  	   Lederle	   W,	   Hartenstein	   B,	   Meides	   A,	   Kunzelmann	   H,	   Werb	   Z,	   Angel	   P,	   Mueller	   MM	   (2009)	  
MMP13	   as	   a	   stromal	   mediator	   in	   controlling	   persistent	   angiogenesis	   in	   skin	   carcinoma.	  
Carcinogenesis.	  
	   39.	  	   Zijlstra	  A,	  Aimes	  RT,	  Zhu	  D,	  Regazzoni	  K,	  Kupriyanova	  T,	   Seandel	  M,	  Deryugina	  EI,	  Quigley	   JP	  
(2004)	   Collagenolysis-­‐dependent	   angiogenesis	   mediated	   by	   matrix	   metalloproteinase-­‐13	  
(collagenase-­‐3).	  J.	  Biol.	  Chem.,	  279:	  27633-­‐27645.	  
	   40.	  	   Kosaki	  N,	  Takaishi	  H,	  Kamekura	  S,	  Kimura	  T,	  Okada	  Y,	  Minqi	  L,	  Amizuka	  N,	  Chung	  UI,	  Nakamura	  
K,	   Kawaguchi	   H,	   Toyama	   Y,	   D'Armiento	   J	   (2007)	   Impaired	   bone	   fracture	   healing	   in	   matrix	  
metalloproteinase-­‐13	  deficient	  mice.	  Biochem.	  Biophys.	  Res.	  Commun.,	  354:	  846-­‐851.	  
	   41.	  	   Lederle	   W,	   Hartenstein	   B,	   Meides	   A,	   Kunzelmann	   H,	   Werb	   Z,	   Angel	   P,	   Mueller	   MM	   (2009)	  
MMP13	   as	   a	   stromal	   mediator	   in	   controlling	   persistent	   angiogenesis	   in	   skin	   carcinoma.	  
Carcinogenesis.	  
	   42.	  	   Inada	  M,	  Wang	  Y,	  Byrne	  MH,	  Rahman	  MU,	  Miyaura	  C,	  Lopez-­‐Otin	  C,	  Krane	  SM	  (2004)	  Critical	  
roles	  for	  collagenase-­‐3	  (Mmp13)	  in	  development	  of	  growth	  plate	  cartilage	  and	  in	  endochondral	  
ossification.	  Proc.	  Natl.	  Acad.	  Sci.	  U.	  S.	  A,	  101:	  17192-­‐17197.	  
	   43.	  	   Knauper	  V,	  Will	  H,	  Lopez-­‐Otin	  C,	  Smith	  B,	  Atkinson	  SJ,	  Stanton	  H,	  Hembry	  RM,	  Murphy	  G	  (1996)	  
Cellular	   mechanisms	   for	   human	   procollagenase-­‐3	   (MMP-­‐13)	   activation.	   Evidence	   that	   MT1-­‐
MMP	  (MMP-­‐14)	  and	  gelatinase	  a	  (MMP-­‐2)	  are	  able	  to	  generate	  active	  enzyme.	  J.	  Biol.	  Chem.,	  
271:	  17124-­‐17131.	  
 12 
	   44.	  	   Lambert	  V,	  Wielockx	  B,	  Munaut	  C,	  Galopin	  C,	   Jost	  M,	   Itoh	  T,	  Werb	  Z,	  Baker	  A,	   Libert	  C,	  Krell	  
HW,	  Foidart	  JM,	  Noel	  A,	  Rakic	  JM	  (2003)	  MMP-­‐2	  and	  MMP-­‐9	  synergize	  in	  promoting	  choroidal	  
neovascularization.	  FASEB	  J.,	  17:	  2290-­‐2292.	  
	   45.	  	   Whitelock	   JM,	   Murdoch	   AD,	   Iozzo	   RV,	   Underwood	   PA	   (1996)	   The	   degradation	   of	   human	  
endothelial	   cell-­‐derived	   perlecan	   and	   release	   of	   bound	   basic	   fibroblast	   growth	   factor	   by	  
stromelysin,	  collagenase,	  plasmin,	  and	  heparanases.	  J.	  Biol.	  Chem.,	  271:	  10079-­‐10086.	  
	   46.	  	   Lederle	   W,	   Hartenstein	   B,	   Meides	   A,	   Kunzelmann	   H,	   Werb	   Z,	   Angel	   P,	   Mueller	   MM	   (2009)	  
MMP13	   as	   a	   stromal	   mediator	   in	   controlling	   persistent	   angiogenesis	   in	   skin	   carcinoma.	  
Carcinogenesis.	  
	   47.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   48.	  	   Asahara	  T,	  Masuda	  H,	  Takahashi	  T,	  Kalka	  C,	  Pastore	  C,	  Silver	  M,	  Kearne	  M,	  Magner	  M,	  Isner	  JM	  
(1999)	   Bone	   marrow	   origin	   of	   endothelial	   progenitor	   cells	   responsible	   for	   postnatal	  
vasculogenesis	  in	  physiological	  and	  pathological	  neovascularization.	  Circ.	  Res.,	  85:	  221-­‐228.	  
	   49.	  	   Sengupta	  N,	  Caballero	  S,	  Mames	  RN,	  Butler	  JM,	  Scott	  EW,	  Grant	  MB	  (2003)	  The	  role	  of	  adult	  
bone	  marrow-­‐derived	  stem	  cells	   in	  choroidal	  neovascularization.	   Invest	  Ophthalmol.	  Vis.	  Sci.,	  
44:	  4908-­‐4913.	  
	   50.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   51.	  	   Sengupta	  N,	  Caballero	  S,	  Mames	  RN,	  Butler	  JM,	  Scott	  EW,	  Grant	  MB	  (2003)	  The	  role	  of	  adult	  
bone	  marrow-­‐derived	  stem	  cells	   in	  choroidal	  neovascularization.	   Invest	  Ophthalmol.	  Vis.	  Sci.,	  
44:	  4908-­‐4913.	  
	   52.	  	   Csaky	  KG,	  Baffi	  JZ,	  Byrnes	  GA,	  Wolfe	  JD,	  Hilmer	  SC,	  Flippin	  J,	  Cousins	  SW	  (2004)	  Recruitment	  of	  
marrow-­‐derived	   endothelial	   cells	   to	   experimental	   choroidal	   neovascularization	   by	   local	  
expression	  of	  vascular	  endothelial	  growth	  factor.	  Exp.	  Eye	  Res.,	  78:	  1107-­‐1116.	  
	   53.	  	   Espinosa-­‐Heidmann	  DG,	  Caicedo	  A,	  Hernandez	  EP,	  Csaky	  KG,	  Cousins	  SW	  (2003)	  Bone	  marrow-­‐
derived	   progenitor	   cells	   contribute	   to	   experimental	   choroidal	   neovascularization.	   Invest	  
Ophthalmol.	  Vis.	  Sci.,	  44:	  4914-­‐4919.	  
	   54.	  	   Tomita	  M,	  Yamada	  H,	  Adachi	  Y,	  Cui	  Y,	  Yamada	  E,	  Higuchi	  A,	  Minamino	  K,	  Suzuki	  Y,	  Matsumura	  
M,	  Ikehara	  S	  (2004)	  Choroidal	  neovascularization	  is	  provided	  by	  bone	  marrow	  cells.	  Stem	  Cells,	  
22:	  21-­‐26.	  
	   55.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   56.	  	   Sengupta	  N,	  Caballero	  S,	  Mames	  RN,	  Butler	  JM,	  Scott	  EW,	  Grant	  MB	  (2003)	  The	  role	  of	  adult	  
bone	  marrow-­‐derived	  stem	  cells	   in	  choroidal	  neovascularization.	   Invest	  Ophthalmol.	  Vis.	  Sci.,	  
44:	  4908-­‐4913.	  
	   57.	  	   Csaky	  KG,	  Baffi	  JZ,	  Byrnes	  GA,	  Wolfe	  JD,	  Hilmer	  SC,	  Flippin	  J,	  Cousins	  SW	  (2004)	  Recruitment	  of	  
marrow-­‐derived	   endothelial	   cells	   to	   experimental	   choroidal	   neovascularization	   by	   local	  
expression	  of	  vascular	  endothelial	  growth	  factor.	  Exp.	  Eye	  Res.,	  78:	  1107-­‐1116.	  
	   58.	  	   Espinosa-­‐Heidmann	  DG,	  Caicedo	  A,	  Hernandez	  EP,	  Csaky	  KG,	  Cousins	  SW	  (2003)	  Bone	  marrow-­‐
derived	   progenitor	   cells	   contribute	   to	   experimental	   choroidal	   neovascularization.	   Invest	  
Ophthalmol.	  Vis.	  Sci.,	  44:	  4914-­‐4919.	  
	   59.	  	   Higashiyama	   R,	   Inagaki	   Y,	   Hong	   YY,	   Kushida	   M,	   Nakao	   S,	   Niioka	   M,	  Watanabe	   T,	   Okano	   H,	  
Matsuzaki	   Y,	   Shiota	   G,	   Okazaki	   I	   (2007)	   Bone	   marrow-­‐derived	   cells	   express	   matrix	  
metalloproteinases	  and	  contribute	  to	  regression	  of	  liver	  fibrosis	  in	  mice.	  Hepatology,	  45:	  213-­‐
222.	  
 13 
	   60.	  	   Udagawa	   T,	   Birsner	   AE,	   Wood	   M,	   D'Amato	   RJ	   (2007)	   Chronic	   suppression	   of	   angiogenesis	  
following	  radiation	  exposure	  is	  independent	  of	  hematopoietic	  reconstitution.	  Cancer	  Res.,	  67:	  
2040-­‐2045.	  
	   61.	  	   Jost	  M,	  Maillard	   C,	   Lecomte	   J,	   Lambert	   V,	   Tjwa	  M,	   Blaise	   P,	   Alvarez	   Gonzalez	  ML,	   Bajou	   K,	  
Blacher	   S,	  Motte	   P,	   Humblet	   C,	   Defresne	  MP,	   Thiry	  M,	   Frankenne	   F,	   Gothot	   A,	   Carmeliet	   P,	  
Rakic	  JM,	  Foidart	  JM,	  Noel	  A	  (2007)	  Tumoral	  and	  choroidal	  vascularization:	  differential	  cellular	  
mechanisms	  involving	  plasminogen	  activator	  inhibitor	  type	  I.	  Am.	  J.	  Pathol.,	  171:	  1369-­‐1380.	  
	   62.	  	   Takaishi	   H,	   Kimura	   T,	   Dalal	   S,	   Okada	   Y,	   D'Armiento	   J	   (2008)	   Joint	   diseases	   and	   matrix	  
metalloproteinases:	  a	  role	  for	  MMP-­‐13.	  Curr.	  Pharm.	  Biotechnol.,	  9:	  47-­‐54.	  
	   63.	  	   Nielsen	   BS,	   Rank	   F,	   Lopez	   JM,	   Balbin	   M,	   Vizoso	   F,	   Lund	   LR,	   Dano	   K,	   Lopez-­‐Otin	   C	   (2001)	  
Collagenase-­‐3	  expression	  in	  breast	  myofibroblasts	  as	  a	  molecular	  marker	  of	  transition	  of	  ductal	  
carcinoma	  in	  situ	  lesions	  to	  invasive	  ductal	  carcinomas.	  Cancer	  Res.,	  61:	  7091-­‐7100.	  
	   64.	  	   Zhang	  B,	  Cao	  X,	  Liu	  Y,	  Cao	  W,	  Zhang	  F,	  Zhang	  S,	  Li	  H,	  Ning	  L,	  Fu	  L,	  Niu	  Y,	  Niu	  R,	  Sun	  B,	  Hao	  X	  
(2008)	  Tumor-­‐derived	  matrix	  metalloproteinase-­‐13	  (MMP-­‐13)	  correlates	  with	  poor	  prognoses	  
of	  invasive	  breast	  cancer.	  BMC.	  Cancer,	  8:	  83.	  
	   65.	  	   Noel	  A,	   Jost	  M,	   Lambert	  V,	   Lecomte	   J,	  Rakic	   JM	   (2007)	  Anti-­‐angiogenic	   therapy	  of	   exudative	  




Figure	  1.	  Mmp13	  expression	  is	  induced	  during	  CNV	  	  
A.	  Representative	  example	  of	  MMP13	  mRNA	  expression	  in	  surgically	  extracted	  choroidal	  neovascular	  
membranes	  of	  patients	  with	  exudative	  AMD	   (1	   to	  3;	  n=3).	   Intact	  posterior	   segments	   from	  healthy	  
donors	  collected	  maximum	  8	  hours	  after	  death	  were	  used	  as	  controls	  (n	  =	  4).	  28S	  rRNA	  and	  GAPDH	  
mRNA	  were	  used	  as	  a	  control	  to	  check	  for	  RNA	  degradation.	  Samples	  were	  harvested	  from	  tissue	  in	  
(M)	  or	  out	  of	  the	  macula	  (O)	  (4	  to	  7;	  n=4).	  	  
B	  and	  C.	  RT-­‐PCR	  analysis	  of	  Mmp13	  mRNA	  expression	  in	  experimental	  CNV	  induced	  by	  laser	  burn	  in	  
mice.	  RNA	  were	  extracted	  from	  the	  entire	  posterior	  segment	  prepared	  at	  different	  times	  (D0	  to	  D14)	  
after	   laser	  burn	  (B).	  Mmp13	  mRNA	  expression	  was	  analyzed	  after	  microdissection	  of	   intact	  choroid	  
(intact	  choroid),	  burned	  choroid	  of	  WT	  mice	  (WT	  lesion)	  and	  Mmp13-­‐/-­‐	  mice	  (Mmp13-­‐/-­‐	  lesion)	  (C).	  The	  
graphs	   illustrate	   the	   densitometric	   quantification	   of	  Mmp13	  mRNA	   expression	   normalized	   to	   28S	  
mRNA.	  (*	  :	  p<0.05;	  **	  :	  p<0.01;	  ***	  :	  p<0.001).	  
	  
Figure	  2.	  Mmp13	  deficiency	  impairs	  CNV	  formation	  
A.	   Confocal	   observation	  of	   neovascularization	  on	   flatmounted	   eyes	   14	  days	   after	   laser	   burn.	  Mice	  
were	   intraveinously	   injected	  with	  FITC-­‐conjugated	  Dextran	  before	   sacrifice.	   Fluorescent	  neovessels	  
were	   visualized	   on	   flatmount	   choroids	   by	   confocal	  microscopy	   and	   their	   areas	  were	   quantified	   by	  
computerized	  analysis	   (graph).	  B.	  Histological	   analysis	  of	   choroidal	   lesion.	   Sections	  of	   laser-­‐burned	  
eyes	  resected	  from	  WT	  and	  Mmp13-­‐/-­‐	  mice	  at	  day	  14	  were	  stained	  with	  hematoxylin-­‐eosin.	  The	  white	  
bars	   delineate	   the	   total	   thickness	   from	   the	   bottom	   of	   choroid	   to	   the	   top	   of	   lesion	   (b)	   and	   the	  
thickness	  of	  adjacent	  normal	  choroid	  (c).	  The	  neovascular	  reaction	  was	  quantified	  by	  determining	  the	  
b/c	  ratio	  (graph).	  Number	  of	  impacts	  per	  experiment	  group:	  Ni=	  36	  to	  40.	  Unpaired	  Student’s	  t	  test	  
was	  used	  as	  statistical	  analysis	  to	  generate	  p	  value.	  (*	  :	  p<0.05;	  ***	  :	  p<0.001)	  
	  
Figure	  3.	  Angiogenesis	   and	   inflammation	  are	   reduced	   in	  neovascular	   lesions	  of	  Mmp13-­‐deficient	  
mice.	  Immunostaining	  was	  performed	  on	  samples	  from	  WT	  and	  Mmp13-­‐/-­‐	  mice.	  	  
A,B	   :	  MMP13	   immunostaining	   (day	  14).	  PECAM	  (red)	  and	  NG2	   (green)	   (C,E)	  or	  αSMA	  (green)	   	   (E,F)	  
double	  immunostaining	  	  (day	  14).	  G,H	  :	  Labelling	  of	  inflammatory	  cells	  using	  CD11b	  antibody	  (day	  5).	  
I,J:	   Staining	   of	   neutrophils	   (day	   5).	  White	   bars	   represent	   100µm;	   yellow	   dotted	   line	   delineate	   the	  
lesion;	  R:	  Retina;	  Ch:	  Choroid;	  inserts	  represent	  a	  2-­‐fold	  higher	  magnification	  of	  initial	  pictures.	  
	  
Figure	  4.	  Bone	  marrow	  transplantation	  restores	  CNV	  formation	  in	  Mmp13-­‐deficient	  mice	  	  
Mice	  were	   irradiated	   (recipient	  mice)	   and	  engrafted	  with	  bone	  marrow	   (BM)	  before	   laser-­‐induced	  
CNV.	  Quantification	  of	  lesion	  was	  performed	  by	  analysing	  the	  size	  of	  CNV	  on	  choroidal	  flatmounts	  (A)	  
and	  histological	  sections	  (B)	  (b/c	  ratio	  as	  described	  in	  Material	  and	  Methods	  and	  in	  Fig.	  1).	  Recipient	  
mice	  and	  BM	  engraftment	  are	  indicated	  below	  each	  graph.	  Number	  of	  impacts	  (Ni)	  per	  experiment	  
group:	  Ni=8	  to	  12.	  (*	  :	  p<0.05;	  **	  :	  p<0.01;	  ***	  :	  p<0.001)	  
	  
Figure	  5.	  MSC	  intraveinous	  injections	  partially	  restore	  CNV	  formation	  in	  MMP13-­‐deficient	  mice	  	  
MSC	   issued	   from	  WT	  mice	  were	   injected	  4	   times	   into	   the	   tail	   vein	  of	   	  WT	   and	  Mmp13-­‐/-­‐	  mice.	  The	  
effects	  of	  MSC	   injection	  on	  CNV	  was	  observed	  at	  day	  14	  after	   laser	   injury.	  Quantification	  of	   lesion	  
areas	  were	  performed	  by	  computer-­‐assisted	   image	  analysis	  as	  described	   in	  Materials	  and	  Methods	  
(see	   also	   legend	  of	   Figure	   1).	  Number	   of	   impacts	   per	   experiment	   group:	  Ni=13-­‐28.	   (*	   :	   p<0.05;	   **	   :	  
p<0.01)	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